

PROVINCIAL FUNDING SUMMARY

Eribulin mesylate (Halaven) for Metastatic Breast Cancer

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: August 20, 2012

This information is current as of August 4, 2016.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Jan 1, 2014	Metastatic or incurable locally advanced breast cancer; ECOG < or equal to 2; previous treatment with a taxane and an anthracycline in either the adjuvant or advanced setting; at least 2 prior regimens for metastatic or locally recurrent disease; 3 of capecitabine, vinorelbine, gemcitabine or eribulin may be used sequentially; adequate hematological, renal and hepatic function. A BCCA "Compassionate Access Program" request with appropriate clinical information must be approved prior to treatment.
AB	Funded	Oct 31, 2013	For the treatment of patients with metastatic or incurable locally advanced breast cancer who have previous treatment with a taxane and an anthracycline, who have had at least two chemotherapy regimens for metastatic or locally recurrent disease and who have progressed after their last therapy. Patients must have good performance status (ECOG \leq 2)
SK	Funded	Oct 1, 2013	Treatment of metastatic or incurable locally advanced breast cancer in patients with a good performance status (ECOG <2) who have had previous treatment with a taxane and an anthracycline, who have had at least two chemotherapy regimens for metastatic or locally recurrent disease, and who have progressed after their last therapy.
MB	Funded	Jul 23, 2013	For the treatment of patients who have: <ul style="list-style-type: none"> •Metastatic or incurable locally advanced breast cancer AND •Received previous treatment with an anthracycline or taxane AND •Disease progression after at least two chemotherapy regimens for advanced disease AND •An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
ON	Funded	July 30, 2013	For metastatic or incurable locally advanced breast cancer where the patient meets the following criteria: -Eribulin is used for the treatment of a patient with metastatic or incurable locally advanced breast cancer who has had previous treatment with a taxane and an anthracycline, who has had at least two chemotherapy regimens for metastatic or locally recurrent disease, and whose disease has progressed after the last therapy; -The patient has good performance status (ECOG \leq 2)
NS	Funded	July 15, 2015	As a single agent for the treatment of metastatic or incurable locally advanced breast cancer for patients who have received previous treatment with a taxane and an anthracycline (in either the adjuvant or metastatic setting), and at least two prior chemotherapy regimens for metastatic or locally advanced disease with evidence of disease progression and an ECOG performance status (PS) \leq 2.
NB	Funded	July 21, 2016	For the treatment of metastatic or incurable locally advanced breast cancer in patients with an ECOG performance status of 0 to 2, who have received previous treatment with a taxane and an anthracycline in either the adjuvant or advanced setting, who have had at least two prior chemotherapy regimens for metastatic or locally advanced disease and, who have progressed following their last therapy.
NL	Funded	Sep 1, 2013	For patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimes including an anthracycline and a taxane and who have progressed again following their last therapy.
PEI	Under provincial consideration*		

* *Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pricing Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.